ITIL-168
Phase 1Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Cancer
Conditions
Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Trial Timeline
Aug 1, 2022 → Dec 8, 2022
NCT ID
NCT05393635About ITIL-168
ITIL-168 is a phase 1 stage product being developed by Instil Bio for Cervical Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05393635. Target conditions include Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer.
What happened to similar drugs?
8 of 20 similar drugs in Cervical Cancer were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05393635 | Phase 1 | Withdrawn |
| NCT05050006 | Phase 2 | Terminated |
Competing Products
20 competing products in Cervical Cancer